Fig. 1

Level of IL-17A in samples from model mice and AD patients with different stages of disease. A mRNA levels of IL-17A in the hippocampus of 2-, 5-, and 9-month-old APP/PS1 mice. n = 5 for each group. B Concentrations of serum IL-17A levels in 2-, 5-, and 9-month-old APP/PS1 mice. n = 5 for each group. C mRNA levels of TNF-α in the hippocampus of 2-, 5-, and 9-month-old APP/PS1 mice. n = 5 for each group. D Relationship of serum IL-17A concentration with escape latency in 9-month-old APP/PS1 mice. E Serum IL-17A levels in AD patients with different stages of disease. F Serum IL-17A levels in patients with AD and other neurodegenerative diseases. G Relationship of the serum IL-17A level with the MoCA score of AD patients according to linear regression analysis. H Relationship of the serum IL-17A level with the MMSE score of AD patients according to linear regression analysis. One-way analysis of variance was used to assess the differences among more than two groups. The values are expressed as the mean ± standard deviation (****P < 0.0001, ***P < 0.001, **P < 0.01, and *P < 0.05). HC: healthy controls; MCI: mild cognitive impairment; DAT: dementia of Alzheimer type; VaD: vascular dementia; PD: Parkinson’s disease. The data are representative of at least three independent experiments